[1] FLENAUGH EL. Tobacco smoking in China: a pulmonary health crisis[J]. Curr Opin Pulm Med, 2019, 25(2): 188. doi: 10.1097/MCP.0000000000000556
[2] HIRSCH FR, SUDA K, WIENS J, et al. New and emerging targeted treatments in advanced non-small-cell lung cancer[J]. Lancet, 2016, 388(10048): 1012. doi: 10.1016/S0140-6736(16)31473-8
[3] SCHENK KM, REUSS JE, CHOQUETTE K, et al. A review of canakinumab and its therapeutic potential for non-small cell lung cancer[J]. Anticancer Drugs, 2019, 30(9): 879. doi: 10.1097/CAD.0000000000000832
[4] YANG J, GONG W. Lorlatinib for the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer[J]. Expert Rev Clin Pharmacol, 2019, 12(3): 173. doi: 10.1080/17512433.2019.1570846
[5] LEONETTI A, SHARMA S, MINARI R, et al. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer[J]. Br J Cancer, 2019, 121(9): 725. doi: 10.1038/s41416-019-0573-8
[6] WU SG, SHIH JY. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer[J]. Mol Cancer, 2018, 17(1): 38. doi: 10.1186/s12943-018-0777-1
[7] HARRISON PT, VYSE S, HUANG PH. Rare epidermal growth factor receptor(EGFR) mutations in non-small cell lung cancer[J]. Semin Cancer Biol, 2020, 61: 167. doi: 10.1016/j.semcancer.2019.09.015
[8] 李向莲, 唐雪莉, 李幼平, 等. EGFR-TKI与化疗比较一线治疗晚期非小细胞肺癌有效性和安全性的系统评价[J]. 中国循证医学杂志, 2016, 2: 191. doi: 10.7507/1672-2531.20160031
[9] 梅馨方, 吴熠. EGFR基因突变状态与非小细胞肺癌病人临床特征及血清肿瘤标志物水平关系分析[J]. 标记免疫分析与临床, 2020, 7: 1198.
[10] CASTELLANOS E, FELD E, HORN L. Driven by mutations: the predictive value of mutation subtype in EGFR-mutated non-small cell lung cancer[J]. J ThoracOncol, 2017, 12(4): 612.
[11] WANG R, WANG G, ZHANG N, et al. Clinical evaluation and cost-effectiveness analysis of serum tumor markers in lung cancer[J]. Biomed Res Int, 2013, 2013: 195692.
[12] 武倩, 马燕粉, 种朝阳, 等. 肿瘤标志物和炎性指标物联合检测对非小细胞肺癌的诊断价值[J]. 蚌埠医学院学报, 2019, 44(12): 1678.
[13] 曲红, 金琳羚, 何梦钰, 等. 149例经手术病理确诊中青年非小细胞肺癌患者临床分析[J]. 徐州医科大学学报, 2020, 40(1): 55.
[14] JONNA S, SUBRAMANIAM DS. Molecular diagnostics and targeted therapies in non-small cell lung cancer(NSCLC): an update[J]. Discov Med, 2019, 27(148): 167.
[15] 张慧芳, 马金沙, 李璐, 等. EGFR-TKIs一线治疗晚期非小细胞肺癌的有效性和安全性比较: 网状Meta分析[J]. 中华疾病控制杂志, 2020, 24(2): 210.
[16] FENG LX, WANG J, YU Z, et al. Clinical significance of serum EGFR gene mutation and serum tumor markers in predicting tyrosine kinase inhibitor efficacy in lung adenocarcinoma[J]. Clin Transl Oncol, 2019, 21(8): 1005. doi: 10.1007/s12094-018-02014-6
[17] WAN R, WANG Z, LEE JJ, et al. Comprehensive analysis of the discordance of EGFR mutation status between tumor tissues and matched circulating tumor dna in advanced non-small cell lung cancer[J]. J Thorac Oncol, 2017, 12(9): 1376. doi: 10.1016/j.jtho.2017.05.011
[18] CHAPMAN AM, SUN KY, RUESTOW P, et al. Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers[J]. Lung Cancer, 2016, 102: 122. doi: 10.1016/j.lungcan.2016.10.010
[19] WANG S, MA P, MA G, et al. Value of serum tumor markers for predicting EGFR mutations and positive ALK expression in 1089 Chinese non-small-cell lung cancer patients: A retrospective analysis[J]. Eur J Cancer, 2020, 124: 1. doi: 10.1016/j.ejca.2019.10.005
[20] CHO A, HUR J, MOON YW, et al. Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer[J]. BMC Cancer, 2016, 16: 224. doi: 10.1186/s12885-016-2251-z